Actavis opens new headquarters in Zug, Switzerland

9 mai 2011 Company to address future challenges with new 'think smart medicine' approach Zug, Switzerland, 9 May 2011 - Actavis Group, the international generic pharmaceutical company, today formally opened its new management offices in Zug, Switzerland. At a press conference to mark the opening of the new headquarters, CEO Claudio Albrecht stated that the generic industry "needs to change." Payors, he said, need modern approaches to cope with exploding health care costs. Albrecht presents Actavis' answer to this in the form of a new tagline for the Company: "think smart medicine". The tagline, he says, relates to a bundle of concepts which should help to cope with this challenge. "This means that we have to come up with more clever concepts, for example offerings in managed care regarding dose dispensing." Actavis must try to be ahead of the generic industry finding new and innovative solutions. With 'think smart medicine' we will address our customers' future needs. Actavis aims to become a global player in diabetes by building an international diabetes franchise around recombinant and analogue insulins. "There are 230 million diabetes patients worldwide. We will be the first company in the future to offer the broadest diabetes portfolio." By challenging traditional thinking Actavis wants to offer direct-to-consumer concepts in the area of dermatology and female health. "Intelligent strategic partnerships will give us the possibility to be one step ahead of our competitors", Albrecht stated. Albrecht explained that the global pharmaceutical landscape will change once many of the current top-sellers lose patent protection over the next few years. "In 2016, out of the top 20 drugs, more than half will be biologics, others will be hard-to-develop generics, such as inhalers." The CEO added that he's not sure there will be such a clear difference between innovator and generic companies in the future. "The lines between the two models are blurring. The generics business as we know it today will be gone within the next ten years. A key challenge for the generic industry - which was used to substitution and key accounting for many years - will also be the required scientific detailing of the new generation of products." Albrecht also commented on the location of the Company's new headquarters. "Zug is centrally located in Switzerland, and close to Zurich, one of Europe's major crossroads. We chose Switzerland because of the outstanding pharmaceutical environment, the availability of qualified personnel, the international atmosphere and the centrally located Zurich Airport." Today around 100 Actavis employees from 29 different countries are based in Zug. By the end of Q2 2011, the Company expects all six floors of the 4,000 sq m building will be fully occupied, with 150 people on site. Actavis is an Icelandic company, founded in 1956. Following a number of acquisitions over the past decade, members of Actavis' top management team were located in Iceland, as well as in various cities in Europe, amongst which were London and Copenhagen. Actavis also evaluated Copenhagen, London and Amsterdam as possible locations before deciding on Zug. # # # # Enquiries Actavis Group Frank Staud EVP Corporate Communication Tel: +41 79 230 95 78 E-mail: fstaud@actavis.com About Actavis Group Actavis is the world's fourth largest generic pharmaceutical company. It specialises in the development, manufacture and sale of generic pharmaceuticals. The Company has operations in more than 40 countries, with over 10,000 employees. Actavis operates 14 manufacturing sites in 12 different countries with a total manufacturing capacity of 24 billion tablets/capsules per annum. For further information on Actavis Group, please visitwww.actavis.com. Any statements contained in this press release that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Actavis via Thomson Reuters ONE [HUG#1513662]